HomeNDC LookupRxCUI directory › RxCUI 2696255

Norethindrone acetate 5 MG Oral Tablet [Gallifrey] — RxCUI 2696255

RxNorm drug concept · Semantic branded drug
RxCUI 2696255 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2696255
Official nameNorethindrone acetate 5 MG Oral Tablet [Gallifrey]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asGallifrey 5 MG Oral Tablet
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)42,432 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Norethindrone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Most norethindrone tablets — including brands like Camila, Errin, Emzahh, and Affodel — are progestin-only birth control pills taken daily to prevent pre...
  • Regular combination birth control pills contain two hormones — estrogen and progestin. Norethindrone is a progestin-only pill, sometimes called the 'mini-pill.' Because it has no e...
  • How is this different from regular birth control pills?
  • The most common thing people notice is irregular bleeding — spotting between periods, or changes in your cycle. Headache, breast tenderness, nausea, and dizziness are also reported...
📖 Read our full Norethindrone guide →

🕸️ Concept Web — How Norethindrone acetate 5 MG Oral Tablet [Gallifre... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Norethindrone acetate 5 MG Oral Tablet [Gallifrey] RxCUI 2696255

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Norethindrone 7514
    • Norethindrone acetate 31983
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Gallifrey 2696249
  3. Dose forms 13

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Norethindrone Oral Tablet 373114
    • Norethindrone acetate Oral Tablet 2648919
    • Norethindrone Oral Product 1159849
    • Norethindrone Pill 1159850
    • Norethindrone acetate Oral Product 2662978
    • Norethindrone acetate Pill 2661083
    • Norethindrone Oral Tablet [Gallifrey] 2696253
    • Norethindrone acetate Oral Tablet [Gallifrey] 2696254
    • +5 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Norethindrone acetate 5 MG Oral Tablet SCD · 1000405
  • Norethindrone acetate 5 MG SCDC · 1000404
  • Norethindrone Oral Tablet SCDF · 373114
  • Norethindrone acetate Oral Tablet SCDFP · 2648919
  • Norethindrone Oral Product SCDG · 1159849
  • Norethindrone Pill SCDG · 1159850
  • Norethindrone acetate Oral Product SCDGP · 2662978
  • Norethindrone acetate Pill SCDGP · 2661083

Brand-Name Concepts

  • Norethindrone acetate 5 MG [Gallifrey] SBDC · 2696250
  • Norethindrone Oral Tablet [Gallifrey] SBDF · 2696253
  • Norethindrone acetate Oral Tablet [Gallifrey] SBDFP · 2696254
  • Gallifrey Oral Product SBDG · 2696251
  • Gallifrey Pill SBDG · 2696252
  • Gallifrey BN · 2696249

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2696255 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
70700-0326-50 50 TABLET in 1 BOTTLE (70700-326-50) Gallifrey Xiromed LLC 2024-09-06
Observed labelers: Xiromed LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.2988
Range $0.2988–$0.2988 · middle 50% $0.2988–$0.2988 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.